Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.

ABSTRACT:

Background/objectives

Frail participants are often under-represented in randomized trials, raising questions about outcomes of interventions in real-world settings. Frailty is strongly associated with vulnerability to illness and adverse health outcomes. We studied the impact of frailty on recombinant zoster vaccine (RZV) clinical outcomes.

Design/setting

Data from two previously conducted phase III randomized trials of RZV were pooled. These two parent trials were conducted concurrently at the same study sites using the same methods.

Participants/intervention

In the two parent studies, participants aged ≥50 years (ZOE-50 study) and ≥70 years (ZOE-70 study), respectively, were randomized 1:1 to receive two doses of RZV or placebo.

Measurements

In the current ZO

SUBMITTER: Curran D 

PROVIDER: S-EPMC7984267 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature